Actavis "for sale" reports emerge
This article was originally published in Scrip
Executive Summary
Rumours are circulating that Actavishas been offered up for sale by its private equity owners for around $6 billion. The Icelandic generics maker is believed to be a likely target for big pharma and a deal could be agreed within five months, according to reports.